ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Clinical trials for ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a new combo therapy improve outcomes for Hard-to-Treat leukemia?
Disease control OngoingThis study is for people newly diagnosed with a specific type of acute myeloid leukemia (AML) linked to prior cancer treatment or other bone marrow disorders. It tests whether adding the drug pomalidomide to standard chemotherapy can improve treatment results. About 50 adults wil…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:55 UTC
-
Immunotherapy boosts leukemia remission in older patients?
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard treatment (azacitidine and venetoclax) helps older adults with newly diagnosed acute myeloid leukemia (AML) achieve deeper remissions and lower the chance of the cancer returning. About 60 participan…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:53 UTC
-
New hope for tough blood cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called olaparib in 14 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to treatment, and who have a specific change in the IDH gene. The drug works by blocking enzymes that cancer cells need to g…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug cocktail aims to control tough leukemia
Disease control OngoingThis early-phase study tests the safety and best dose of combining bortezomib, sorafenib, and decitabine for adults with acute myeloid leukemia (AML). It includes older patients who cannot have standard treatment or those whose leukemia has returned. The goal is to find a tolerab…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Immunotherapy boosts standard chemo in AML trial
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve deeper remission. About 49 adults with AML, including those whose cancer arose from prior conditions, will receive …
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New hope for kids with relapsed leukemia: drug combo targets hidden cancer cells
Disease control OngoingThis early-phase trial tests a new drug called uproleselan combined with standard chemotherapy (fludarabine and cytarabine) in children and teens with acute myeloid leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia that has returned or not responded to treatme…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC